Arimoclomol in Sporadic Inclusion Body Myositis

Status Completed

Clinical Trial Summary

Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability of Arimoclomol in IBM as compared to placebo over 4 months of treatment.

Clinical Trial Description

IBM is a chronic disorder in which muscles become inflamed (swollen) and cause muscle weakening. The cause is unknown. There is new evidence to suggest that the pathology in IBM results from cellular changes induced by a variety of stressful events and diseases. In response to these stressful events the body's normal response is to increase the levels of Heat Shock Proteins (HSP) to help counteract and stop these cellular changes. In people with IBM this increase does not appear sufficient enough to reverse these toxic cellular changes. Arimoclomol causes the body to make more of this HSP protein. By increasing HSP levels in IBM patients we hope to reverse the toxic cellular changes that might be responsible for the pathology of IBM. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00769860
Study type	Interventional
Source	University of Kansas Medical Center
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	September 2008
Completion date	September 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01165008` - Anakinra in Myositis	Phase 2/Phase 3
Recruiting	`NCT05890833` - The Risk of Falls Index for Patients With Neuromuscular Disorders
Active, not recruiting	`NCT05046821` - Sporadic Inclusion Body Myositis Natural History Study
Recruiting	`NCT06153108` - Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
Active, not recruiting	`NCT04659031` - A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)	Phase 1
Completed	`NCT03440034` - Study of Pioglitazone in Sporadic Inclusion Body Myositis	Phase 1
Terminated	`NCT04049097` - Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial	Phase 3
Completed	`NCT00001261` - Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies	Phase 2
Recruiting	`NCT05272969` - Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
Completed	`NCT01734369` - Environmental Risk Factors for Myositis in Military Personnel
Active, not recruiting	`NCT04975841` - Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells	N/A
Recruiting	`NCT00017914` - Adult and Juvenile Myositis
Completed	`NCT00917956` - Lithium in Inclusion Body Myositis (IBM)	N/A
Completed	`NCT03633318` - Establishing Muscle Impedance Parameters With Electrical Impedance Myography
Recruiting	`NCT04789070` - Phase III Trial of Sirolimus in IBM	Phase 3
Active, not recruiting	`NCT05721573` - A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis	Phase 2/Phase 3
Recruiting	`NCT05032131` - Cell Therapy for IBM by Muscle Injection of ADSVF	Phase 1
Completed	`NCT03299335` - Molecular Profile of the Evolution of Inclusion Body Myositis	N/A
Completed	`NCT04421677` - Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis	Phase 1
Completed	`NCT02753530` - Study of Arimoclomol in Inclusion Body Myositis (IBM)	Phase 2